Bumetanide Pregnancy and Breastfeeding Warnings
Brand names: Bumex
Medically reviewed by Drugs.com. Last updated on Aug 3, 2023.
Bumetanide Pregnancy Warnings
Bumetanide has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of teratogenicity. A dose-related decrease in litter size and an increase in resorption rate were noted in rabbits at doses between 3.4 and 10 times the maximum recommended therapeutic human dose (on a per kg basis). There are no data from human pregnancy studies. Bumetanide should only be given during pregnancy when benefit outweighs risk.
Bumetanide Breastfeeding Warnings
There are no data on the excretion of bumetanide into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
See also
References for pregnancy information
- Ward A, Heel RC (1984) "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs, 28, p. 426-64
- (2002) "Product Information. Bumex (bumetanide)." Roche Laboratories
References for breastfeeding information
- Ward A, Heel RC (1984) "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs, 28, p. 426-64
- (2002) "Product Information. Bumex (bumetanide)." Roche Laboratories
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.